Key result
Aspirin reduces the risk of both arterial and venous thromboembolic events by approximately 25%, but is associated with a 75% increased risk of bleeding.
Design
Review
Authors
Loading...
Requires individualized aspirin risk-benefit assessment; extends literature synthesis for antithrombotic research.
This review provides a comprehensive overview of the pathophysiology of thrombosis, the efficacy and bleeding risks of antithrombotic therapies, and the clinical and biochemical endpoints used to measure their effects.
Gordon Lowe (2002) conducted a review in Thrombosis. Antithrombotic therapies was evaluated. Aspirin reduces the risk of both arterial and venous thromboembolic events by approximately 25%, but is associated with a 75% increased risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: